Drugs / 89Zr-TLX250
89Zr-TLX250
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07179770 | Sep 2025 → Sep 2027 expected | clear cell renal carcinoma | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 1 | NCT05861778 | Jun → Nov 2023 | clear cell renal carcinoma | Telix Pharmaceuticals (Innovations) Pty Limited | Completed | No outcome recorded |
| Phase 1 | NCT05046665 | May 2021 → Aug 2022 | urothelial carcinoma | South Metropolitan Health Service | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07077083 | Mar 2026 → Aug 2027 expected | clear cell renal carcinoma | Massachusetts General Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04758780 | Sep 2021 → Mar 2023 | triple-negative breast carcinoma | Institut Cancerologie de l'Ouest | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06750419 | Nov 2024 → Jun 2026 overdue | clear cell renal carcinoma | Telix Pharmaceuticals (Innovations) Pty Limited | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zr-TLX250 | “The study is designed to evaluate the safety, tolerability, radiation dosimetry and pharmacokinetics 89Zr-TLX250 (also known as 89Zr-DFO-girentuximab) Positron Emission...” NCT05861778 ↗3“89Zirconium-labelled girentuximab (89Zr-TLX250) may have utility in the accurate staging of bladder and urothelial carcinomas, with less renal excretion as compared with FDG;...” PMID 35428649 ↗ Apr 2022 |
| Known as | 89Zr-DFO-girentuximab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07179770 ↗ |
| Known as | 89Zr-Girentuximab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07077083 ↗ |
| Known as | girentuximab | “89Zr-TLX250, is a chimeric monoclonal antibody (INN name: girentuximab) with specificity for the CAIX (carbonic anhydrase 9) antigen, radiolabelled with the positron emitting...” NCT06750419 ↗ |
| Known as | TLX250-CDx | “[89Zr]Zr-DFO-89Zr-girentuximab (TLX250-CDx) positron emission tomography/computed tomography (PET/CT)” PMID 41174094 ↗ Nov 2025 |
| Modality | Monoclonal antibody | “a radiolabeled monoclonal antibody that recognizes carbonic anhydrase IX (CAIX)” NCT04758780 ↗ |
| Route | Intravenous | “Intravenous administration of 37±10% MBq TLX250-CDx was performed” PMID 41174094 ↗ Nov 2025 |